GENOMIC TESTING

Almost one-third of patients became newly eligible for treatment after identification of a previously undetected druggable mutation.

Nationwide data show CGP turnaround improves, but biopsy-to-order delays vary widely, slowing biomarker-driven care in lung and solid tumors.

The FDA's Molecular and Clinical Genetics Panel will meet Sept. 23, 2026, to evaluate GRAIL's premarket approval application for the Galleri MCED test.

Large Ontario cohort study finds lifetime breast and ovarian cancer risk varies sharply by BRCA1/BRCA2 test result, including in those with inconclusive or negative findings.

Large genomic study shows BRCA2 breast cancers rapidly lose RB1, resisting CDK4/6 therapy; PARP inhibitors may work better and move to first line.

The PTEN IHC CDx is a companion diagnostic approved by the FDA to determine patients' eligibility for capivasertib in metastatic prostate cancer.

Genome sequencing speeds tumor mutation discovery, boosting targeted cancer therapies and cell/gene treatments while raising urgent questions about data ownership, reporting uncertainty, and ethics.

MammaPrint in the FLEX registry predicts which HR+/HER2– early breast cancers benefit from anthracyclines—guiding safer, personalized chemo.

Advanced genomic profiling in community oncology uncovers actionable cancer mutations and trial options—yet insurance denials still block access.

New data show precision cancer testing still lags for Black, Hispanic, low-income, and Medicare/Medicaid patients, delaying targeted treatment decisions.

New study reveals a blood-based test effectively detects cancers in survivors, bridging the surveillance gap and enhancing long-term monitoring.

The FDA approves a new diagnostic kit for identifying acute leukemia patients eligible for the groundbreaking Menin inhibitor, revumenib.

A groundbreaking study reveals that Guardant Reveal's liquid biopsy detects immunotherapy responses earlier, enhancing treatment decisions for advanced cancer patients.

A recent study highlights the rising yet inadequate rates of biomarker testing in advanced cancers, emphasizing the need for improved access to optimize patient outcomes.

Advancements in cancer care focus on precise detection of measurable residual disease, enhancing monitoring and relapse prediction through innovative technologies and AI integration.